ABSTRACT

**Aims/Introduction:** The present study was designed to evaluate the effect of chromium malate on glycometabolism, glycometabolism-related enzyme levels and lipid metabolism in type 2 diabetic rats, and dose–response and curative effects.

**Materials and Methods:** The model of type 2 diabetes rats was developed, and daily treatment with chromium malate was given for 4 weeks. A rat enzyme-linked immunosorbent assay kit was used to assay glycometabolism, glycometabolism-related enzyme levels and lipid metabolism changes.

**Results:** The results showed that the antihyperglycemic activity increased with administration of chromium malate in a dose–dependent manner. The serum insulin level, insulin resistance index and C-peptide level of the chromium malate groups at a dose of 17.5, 20.0 and 20.8 μg chromium/kg bodyweight were significantly lower than that of the model, chromium trichloride and chromium picolinate groups. The hepatic glycogen, glucose-6-phosphate dehydrogenase and glucokinase levels of the chromium malate groups at a dose of 17.5, 20.0 and 20.8 μg chromium/kg bodyweight were significantly higher than that of the model, chromium trichloride and chromium picolinate groups. Chromium malate at a dose of 20.0 and 20.8 μg chromium/kg bodyweight significantly changed the total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides levels compared with the chromium trichloride and chromium picolinate groups.

**Conclusions:** The results showed that chromium malate exhibits greater benefits in treating type 2 diabetes, and the curative effect of chromium malate is superior to chromium trichloride and chromium picolinate.

INTRODUCTION

Diabetes mellitus has been identified as one of the three diseases (cardiovascular diseases, cancer and diabetes mellitus) difficult to cure by the World Health Organization. It was mainly divided into type 1 diabetes and type 2 diabetes. Type 2 diabetes, which appears in middle-aged people and the elderly, was the focus of the present research. It accounts for more than 90% of diabetes cases. Furthermore, the age of type 2 diabetes patients showed a downward trend. The occurrence of type 2 diabetes has been associated with genetic and acquired factors. Type 2 diabetes is accompanied by glycometabolism, glycometabolism-related enzymes, lipid metabolism disorders and so on. The complications of type 2 diabetes are coronary heart disease, low learning deficits, low cognitive ability and cardiovascular disease. However, type 2 diabetes and its complications...
cannot be cured completely, and prescribed medication and supplements should be given priority. Chromium (Cr\(^{3+}\)), magnesium, multivitamins, calcium and aspirin are used as over-the-counter supplements.

Studies have shown that Cr\(^{3+}\) and its complex can decrease fasting blood glucose level. Cr can enhance insulin sensitivity and regulate lipid metabolism in diabetes. Studies have reported that supplemental Cr\(^{3+}\) propionate complex can significantly decrease serum insulin levels and increase the insulin sensitivity index. Similar results were reported that Cr\(^{4+}\) propionate complex can significantly reduce serum triacylglycerols, total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Chromium supplementation can significantly reduce total cholesterol (TC), triglyceride (TG) and LDL levels in type 2 diabetes patients. Currently, inorganic chromium and organic chromium are two categories of chromium supplements. Inorganic chromium complex, including chromium trichloride and chromium nitrate, have low absorption and high toxicity compared with organic chromium complex. Chromium picolinate, chromium nicotinate and chromium yeast are organic chromium complexes, and have been widely used as supplements. However, studies have shown that chromium picolinate can result in genotoxicity and cytotoxicity, thus its safety is a concern. The poor solubility and unstable structure of chromium nicotinate and chromium yeast have limited their application, respectively. Therefore, a novel and non-toxic organic chromium complex with antihyperglycemic activity has become an important issue.

Chromium malate is a new type of organic chromium complex that has been synthesized by our research group. Chromium malate was synthesized by chelating Cr\(^{3+}\) with L-malic acid, which was selected as the natural ligand. Its chemical formula and molecular weight are \(\text{Cr}_2\text{C}_4\text{H}_2\text{O}_6\) (or \(\text{Cr}_2[\text{C}_4\text{H}_4\text{O}_5]_3\cdot 5\text{H}_2\text{O}\)) and 590.18 g/mol, respectively. Chromium malate can control blood glucose levels in alloxan-induced diabetic mice and does not cause oxidative DNA damage, and was tested as non-toxic in acute and subacute toxicity studies. The dose–response relationship of chromium malate was examined in the present study. The effect of chromium malate on improving glycometabolism, glycometabolism-related enzymes and lipid metabolism in type 2 diabetic rats was also studied.

**METHODS**

**Ethics Statement**

All the experimental procedures were carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans, the EC Directive 86/609/EEC for animal experiments, and were approved by the Jiangsu University Committee on Animal Care and Use. Sprague–Dawley rats were procured from Jiangsu University (license number SYXX [SU] 2013–0036). The Sprague–Dawley rat is not a protected or endangered species. Our experiments complied with the laws and ethical recommendations currently in effect in China where the experiments were carried out.

**Materials and Chemicals**

The chromium malate was synthesized in our previous study. The raw materials were purchased from Sinopharm Chemical Reagent Co., Ltd (Shanghai, China). Streptozotocin was obtained from Sigma Chemical Co. (St. Louis, MO, USA) Distilled water was used throughout all the experiments. The “glycogen kit” was purchased from Nanjing Jincheng Bioengineering Institute (Nanjing, China). Rat enzyme-linked immunosorbent assay (ELISA) kits were purchased from Hefei Bomei Biotechnology Co., Ltd (Hefei, China).

**Animals and Diet**

A total of 200 Sprague–Dawley male rats with an average weight of 180 ± 10 g were purchased from Jiangsu University.

| Group                          | Rats                                      | Dose (Cr, \(\mu\)g/kg bw) |
|-------------------------------|-------------------------------------------|---------------------------|
| Normal control group          | Normal rats                               | –                         |
| Model group                   | Type 2 diabetic rats                       | –                         |
| Chromium trichloride-treated  | Type 2 diabetic rats                       | 20.8                      |
| group                         |                                           |                           |
| Chromium picolinate-treated   | Type 2 diabetic rats                       | 20.8                      |
| group                         |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 2.5                       |
| group 1                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 5.0                       |
| group 2                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 7.5                       |
| group 3                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 10.0                      |
| group 4                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 12.5                      |
| group 5                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 15.0                      |
| group 6                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 17.5                      |
| group 7                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 20.0                      |
| group 8                       |                                           |                           |
| Chromium malate-treated       | Type 2 diabetic rats                       | 20.8                      |
| group 9                       |                                           |                           |
| Chromium malate control group | Normal rats                               | 20.8                      |

BW, bodyweight; Cr, chromium.
for all the experiments. Before the experiment, the animals were allowed 3 days for environmental and trainer handling acclimatization. The temperatures and relative humidity of the animal house were 24 ± 1°C and 55–60%, respectively. Rats consumed distilled water during the entire experimental period.

Models of Type 2 Diabetes
The models of type 2 diabetes were developed using the method of Li et al. and Xu et al. with slight modification26,27. A high-sugar and high-fat diet was supplied to rats in the first 2 months. Then the rats were injected with streptozotocin at a dose of 30 mg/kg bodyweight through intraperitoneal injection. Fasting blood glucose (FBG) level was measured by a one touch glucometer 3 days later. The oral glucose tolerance test and insulin resistance test were carried out. The FBG level of 33.3 mmol/L > FBG ≥ 11.1 mmol/L, accompanied by oral glucose tolerance and reduced insulin resistance (IR) in rats was taken as a successful induction of type 2 diabetes.

Dose–Response Relationship
Antihyperglycemic Activity
The type 2 diabetic rats were randomly divided into 12 groups of 10 animals. The experiment design, and the dose of chromium malate, chromium trichloride and chromium picolinate are shown in Table 1. Chromium malate was given by oral gavage to rats. Chromium trichloride and chromium picolinate were used as a positive control. The content of Cr in a standard pellet diet is 4.63 μg/kg. The Cr content, which was consumed by rats, is less than 1 μg, therefore, there has no obvious effect on this test. Normal rats were used as experimental animals in a blank control group and chromium malate control group. The type 2 diabetic rats were treated with chromium malate daily by gavage for 4 weeks. FBG and body mass were tested once a week. Blood samples were collected and centrifuged at the end of the experiment. The anticoagulated blood and the blood serum were used for hematological and biochemical analyses.

Glycometabolism and Glycometabolism-Related Enzymes
The serum and liver of rats were collected when the rats were killed. Serum insulin and C-peptide (C-P) were assayed by rat ELISA kits. The IR index was calculated by the following formula:28.

\[ IR = \frac{\text{insulin}}{22.5e^{-\ln \text{FBG}}} \]

A glycogen kit was used to assay liver glycogen levels. The livers of rats were homogenized and centrifuged at 5,000 g for 10 min at 4°C, and then supernatant was collected. Rat ELISA kits were used to estimate glucose-6-phosphate dehydrogenase (G6PD) and glucokinase (GCK) activity in the liver supernatant.

Lipid Metabolism
The serum of rats, which was collected in the previous step, was used to measure lipid metabolism analysis. TC, LDL, high-density lipoprotein cholesterol (HDL) and TG levels in blood serum were assayed by a rat reagent kit (Dong’ou Jinma Technology, Co., Ltd., Zhejiang, China).

Cr Content
The Vista-MPX Simultaneous Inductively coupled plasma (ICP) method (Varian, Inc., Palo Alto, CA, USA) was used to
measure Cr content in the serum and organs (heart, liver, spleen, lung, kidney, brain) of rats. Cr was determined after wet digestion according to the method described by Wu et al.\textsuperscript{24} and Sereshti et al.\textsuperscript{29} The serum and organs of rats were joined in nitric acid and perchloric acid (1:4, v/v) to digestion.

**Organ Index**
The organs (heart, liver, spleen, lung, kidney, brain) of rats, which were collected in the previous step, were weighed. Relative heart/liver/spleen/lung/kidney/brain weights were expressed as the ratio of the heart/liver/spleen/lung/kidney/brain to body-weight (mg/g).

**Statistical Analysis**
Statistical analyses were carried out by the program SPSS 16.0 (Chicago, IL, USA). One-way analysis of variance (ANOVA) was used for data analysis. The Tukey test for multiple comparisons among the groups was carried out to determine significant differences. $P < 0.05$ was considered as statistically significant.

**RESULTS**

**Dose–Response Relationship of Chromium Malate Antihyperglycemic Activity**
The dose–response relationship of chromium malate in antihyperglycemic activity during the fourth week is shown in Figure 1a. It can be observed that the FBG level of the chromium malate-treated groups showed a trend of decline in type 2 diabetic rats after the administration of chromium malate. The antihyperglycemic activity increased with an increase in dose of chromium malate. The FBG level of type 2 diabetic rats remained at 11–12 mmol/L after administration with chromium malate at a dose of 20.0 and 20.8 $\mu$g Cr/kg.
bodyweight. The antihyperglycemic activity of chromium malate shows a dose dependency. The FBG level of chromium malate-treated groups at a dose of 7.5, 10.0, 12.5, 15.0, 17.5, 20.0 and 20.8 µg Cr/kg bodyweight was significantly lower than that of the model group (Figure 1b). It can be observed that chromium trichloride and chromium picolinate can reduce FBG level. The FBG level of the chromium picolinate-treated group and chromium trichloride-treated group was significantly decreased when compared with the model group. From these results, it can be deduced that the FBG level of the chromium malate-treated groups at a dose of 7.5, 10.0, 12.5, 15.0, 17.5, 20.0 and 20.8 µg Cr/kg bodyweight was significantly lower than that of the chromium trichloride-treated group at a dose of 20.8 µg Cr/kg bodyweight (20.82 ± 2.04 mmol/L) and the chromium picolinate-treated group at a dose of 20.0 µg Cr/kg bodyweight (18.57 ± 1.88 mmol/L). The antihyperglycemic activity of chromium malate was better than that of chromium trichloride and chromium picolinate.

**Glycometabolism**

The changes in serum insulin, IR, C-P and hepatic glycogen levels of normal rats and type 2 diabetic rats after administration of chromium malate, chromium trichloride and chromium picolinate are shown in Figure 2. Chromium malate, chromium trichloride and chromium picolinate can reduce serum insulin, IR and C-P levels in type 2 diabetic rats (Figure 2a–c). The serum insulin, IR and C-P levels of chromium malate-treated groups at a dose of 17.5, 20.0 and 20.8 µg Cr/kg bodyweight was significantly different when compared with the model group. The serum insulin, IR and C-P level reduced with an increase in dose of chromium malate. The hepatic glycogen level was increased after administration of chromium malate and chromium picolinate in type 2 diabetic rats (Figure 2d). Chromium trichloride cannot increase the hepatic glycogen level in type 2 diabetic rats. The hepatic glycogen level increased with an increase in dose of chromium malate. The hepatic glycogen level of the chromium malate-treated groups at a dose of 12.5, 15.0, 17.5, 20.0 and 20.8 µg Cr/kg bodyweight was significantly higher than that of the model group, chromium trichloride-treated group and chromium picolinate-treated group. However, the chromium trichloride- and chromium picolinate-treated groups showed no significant change when compared with the model group. The serum insulin, IR and C-P level reduced with an increase in dose of chromium malate. The hepatic glycogen level was increased after administration of chromium malate and chromium picolinate in type 2 diabetic rats (Figure 2d). Chromium trichloride cannot increase the hepatic glycogen level in type 2 diabetic rats. The hepatic glycogen level increased with an increase in dose of chromium malate. The hepatic glycogen level of the chromium malate-treated groups at a dose of 12.5, 15.0, 17.5, 20.0 and 20.8 µg Cr/kg bodyweight was significantly higher than that of the model group, chromium trichloride-treated group and chromium picolinate-treated group. The hepatic glycogen level of the chromium picolinate-treated group showed no significant increase when compared with the model group. The curative effects of chromium malate on the changes of serum insulin, IR, C-P and hepatic glycogen levels are better than those of chromium trichloride and chromium picolinate.

**Glycometabolism-Related Enzymes**

The changes in G6PD and GCK levels of normal rats and type 2 diabetic rats after administration of chromium malate, chromium trichloride and chromium picolinate are shown in Figure 3. Chromium trichloride and chromium picolinate can increase the content of G6PD and GCK in type 2 diabetic rats. However, the G6PD and GCK levels of chromium trichloride-treated group and chromium picolinate-treated group showed no significantly increase when compared with model group. The results indicated that chromium malate can increase the G6PD and GCK level in type 2 diabetic rats. The G6PD and GCK levels increased with an increase in dose of chromium malate. The G6PD level of the chromium malate-treated groups at a dose of 17.5, 20.0 and 20.8 µg Cr/kg bodyweight was significantly increased when compared with the model group, chromium trichloride-treated group and chromium picolinate-treated group. The GCK level of the chromium
malate-treated groups at a dose of 12.5, 15.0, 17.5, 20.0 and 20.8 μg Cr/kg bodyweight was significantly increased when compared with the model group, chromium trichloride-treated group and chromium picolinate-treated group. The curative effects of chromium malate on increased G6PD and GCK levels are better than those of chromium trichloride and chromium picolinate.

Lipid Metabolism

The changes in TC, LDL, HDL and TG levels of normal rats and type 2 diabetic rats after administration chromium malate, chromium trichloride and chromium picolinate are shown in Figure 4. Chromium trichloride and chromium picolinate can reduce serum TC, LDL and TG levels, and increase serum HDL levels in type 2 diabetic rats. However, chromium trichloride and chromium picolinate cannot significantly reduce serum TC, LDL and TG levels, or increase serum HDL levels when compared with the model group. The results showed that chromium malate can reduce the serum TC, LDL and TG levels, and increase serum HDL levels. The TC, LDL and TG levels reduced with an increase in dose of chromium malate. Serum HDL levels increased with an increase in dose of chromium malate. The TC, HDL and TG levels of the chromium malate-treated groups at a dose of 17.5, 20.0 and 20.8 μg Cr/kg bodyweight significantly changed when compared with the model group, chromium trichloride-treated group and chromium picolinate-treated group. The curative effects of chromium malate on reducing TC, LDL and TG levels, and increasing HDL levels are better than those of chromium trichloride and chromium picolinate.
**Table 2 | Chromium content of normal rats and type 2 diabetic rats after administration of chromium malate, chromium trichloride and chromium picolinate, and changes in serum and organs**

| Group                          | Parameter | µg/mL | µg/g |
|-------------------------------|-----------|-------|------|
|                               | Serum     | Heart | Liver| Spleen| Lung | Kidney| Brain|
| Normal control group          | 15.28 ± 1.06 | 6.29 ± 2.01 | 5.97 ± 2.12 | 10.45 ± 2.49 | 14.54 ± 2.01 | 9.32 ± 2.27 | 9.98 ± 2.27 |
| Model group                   | 10.01 ± 1.05† | 5.91 ± 1.38 | 5.88 ± 1.24 | 9.74 ± 2.75 | 13.98 ± 2.92 | 7.58 ± 2.50 | 8.59 ± 2.13 |
| Chromium trichloride-treated group | 12.03 ± 1.13† | 5.93 ± 2.17 | 6.01 ± 2.19 | 11.00 ± 3.62 | 13.06 ± 4.30 | 8.64 ± 3.06 | 9.46 ± 3.27 |
| Chromium picolinate-treated group | 17.14 ± 1.51† | 7.12 ± 4.28 | 5.84 ± 1.87 | 11.97 ± 4.19 | 14.56 ± 4.31 | 10.37 ± 3.24 | 10.58 ± 3.25 |
| Chromium malate-treated group 1 | 10.47 ± 1.27† | 5.30 ± 2.23 | 5.84 ± 2.58 | 9.86 ± 2.59 | 13.91 ± 2.67 | 7.93 ± 2.48 | 8.51 ± 2.02 |
| Chromium malate-treated group 2 | 10.94 ± 1.47† | 5.72 ± 2.14 | 5.97 ± 1.98 | 9.92 ± 3.01 | 13.98 ± 2.64 | 8.55 ± 2.30 | 8.69 ± 2.85 |
| Chromium malate-treated group 3 | 11.01 ± 1.05† | 6.02 ± 2.01 | 5.91 ± 2.24 | 10.06 ± 3.21 | 13.98 ± 3.82 | 8.99 ± 3.01 | 8.82 ± 3.02 |
| Chromium malate-treated group 4 | 11.25 ± 1.34† | 6.18 ± 2.26 | 5.95 ± 2.33 | 10.58 ± 3.51 | 14.12 ± 2.52 | 9.49 ± 2.15 | 9.03 ± 2.34 |
| Chromium malate-treated group 5 | 13.77 ± 1.29† | 6.50 ± 2.12 | 5.97 ± 2.56 | 11.36 ± 3.90 | 14.15 ± 3.92 | 10.01 ± 2.59 | 9.20 ± 3.09 |
| Chromium malate-treated group 6 | 16.42 ± 1.65† | 6.63 ± 2.48 | 6.00 ± 3.53 | 13.36 ± 5.04 | 14.22 ± 4.43 | 10.48 ± 3.43 | 10.36 ± 3.41 |
| Chromium malate-treated group 7 | 17.04 ± 1.53† | 7.16 ± 3.47 | 6.00 ± 2.62 | 14.55 ± 3.37 | 14.39 ± 3.21 | 10.76 ± 3.41 | 10.21 ± 3.36 |
| Chromium malate-treated group 8 | 17.68 ± 1.30† | 7.91 ± 3.14 | 6.03 ± 2.21 | 15.58 ± 4.53 | 14.59 ± 4.03 | 11.00 ± 3.62 | 10.34 ± 3.41 |
| Chromium malate-treated group 9 | 17.98 ± 1.17† | 8.09 ± 3.54 | 6.06 ± 1.29 | 16.09 ± 5.21 | 14.60 ± 5.01 | 11.02 ± 4.23 | 10.82 ± 4.05 |
| Chromium malate control group  | 15.45 ± 1.24† | 6.39 ± 2.10 | 5.97 ± 2.67 | 12.31 ± 4.53 | 14.41 ± 4.86 | 10.69 ± 4.41 | 11.26 ± 4.16 |

Data is presented as mean ± standard deviation (n = 10). Chromium trichloride and chromium picolinate were used as positive controls. †Significantly different from normal control group (P < 0.05). ‡Significantly different from model group (P < 0.05). §Significantly different from chromium trichloride-treated group (P < 0.05). ¶Significantly different from chromium picolinate-treated group (P < 0.05).

**Figure 5 | The dose–response relationship of chromium malate in the body mass of normal and type 2 diabetic rats in the fourth week.** Chromium trichloride and chromium picolinate were used as positive controls. Each value was presented as mean ± SD (n = 10). *Significantly different from normal control group (P < 0.05). †Significantly different from model group (P < 0.05). ‡Significantly different from chromium trichloride-treated group (P < 0.05). ¶Significantly different from chromium picolinate-treated group (P < 0.05).

**Cr Content**

The changes in Cr content in the serum and organs (heart, liver, spleen, lung, kidney, brain) of normal rats and type 2 diabetic rats after administration of chromium malate, chromium trichloride and chromium picolinate are shown in Table 2. The serum Cr content of the normal control group was significantly higher than that of the model group. The results showed that type 2 diabetes can reduce serum Cr content, and chromium malate, chromium trichloride and chromium picolinate can increase the serum Cr content in type 2 diabetic rats. The serum Cr content of the chromium malate-treated group at a dose of 15.0, 17.5, 20.0 and 20.8 µg Cr/kg bodyweight, and the chromium picolinate-treated group was significantly increased when compared with the chromium trichloride-treated group. The results showed that the absorption of chromium malate and chromium picolinate was higher than that of chromium trichloride, and the absorption rate of chromium malate was the same as chromium picolinate. The Cr content in organs (heart, liver, spleen, lung, kidney, brain) of the model group showed no significant decrease when compared with the normal control group, chromium malate-treated group, chromium trichloride-treated group and chromium picolinate-treated group. The Cr content of the chromium malate-treated group at a dose of 20.8 µg Cr/kg bodyweight is spleen > lung > kidney > brain > heart > liver.

**Dose–Response Relationship of Chromium Malate in Body Mass**

The dose–response relationship of chromium malate in the body mass of normal rats and type 2 diabetic rats in the fourth week is shown in Figure 5. It can be observed that the body mass of type 2 diabetic rats increased with an increase in chromium malate. The body mass of the chromium malate-treated groups at a dose of 15.0, 17.5, 20.0 and 20.8 µg Cr/kg
bodyweight showed a significant increase when compared with the model group. However, there was no significant increase when compared with the chromium chloride-treated group and chromium picolinate-treated group. Chromium chloride and chromium picolinate can increase the body mass of type 2 diabetic rats. However, there was no significant change when compared with the model group. These results showed that chromium malate did not have a significant effect on absolute and relative organ weights in rats.

**DISCUSSION**

Diabetes mellitus is a chronic disease affecting millions of people globally and resulting in significant death rates each year. Type 2 diabetes is one type of diabetes mellitus and is found all over the world including China. It is also characterized by hyperglycemia and insulin resistance. Type 2 diabetic rats showed significant hyperglycemia in the present study. The FBG level of type 2 diabetic rats was 22.46 ± 1.47 mmol/L and significantly higher than that of normal rats (5.82 ± 0.53 mmol/L).

Cr is an important micronutrient that can reduce the FBG level in diabetes mellitus. Similar results were reported by Pattar et al., who found that chromium picolinate can enhance glucose metabolism; however, the safety and dose problems of chromium picolinate have been a concern. Chromium malate reduced FBG levels in type 2 diabetic rats after administration of chromium malate in the present study. Hepatic glycogen is composed of glucose and stored in the liver. Its accumulation is promoted by hyperglycemia and insulin, and in diabetes patients it is often accompanied by lower hepatic glycogen level. The results of the present study showed that the hepatic glycogen levels of type 2 diabetic rats were significantly lower.
### Table 4 | Hematological analyses in normal rats and type 2 diabetic rats after administration of chromium malate, chromium trichloride and chromium picolinate

| Group                          | Parameter                  | WBC (10^9/L) | LYMPH (10^9/L)† | MNCC (10^9/L) | NCC (10^9/L) | RBC (10^12/L) | HCT (%) | MCV (fl) |
|-------------------------------|----------------------------|--------------|-----------------|--------------|-------------|---------------|---------|---------|
| Normal control group          |                            | 8.04 ± 1.99  | 8.15 ± 2.11     | 0.85 ± 0.49  | 1.40 ± 0.18 | 8.71 ± 0.10   | 46.76 ± 4.38 | 55.00 ± 1.71 |
| Model group                   |                            | 13.45 ± 1.93 | 5.87 ± 0.94     | 0.62 ± 0.21  | 2.42 ± 0.26 | 9.61 ± 0.31   | 52.66 ± 1.43 | 57.33 ± 1.75 |
| Chromium trichloride-treated group |                   | 12.41 ± 1.61 | 5.27 ± 1.53     | 0.61 ± 0.20  | 2.07 ± 0.40 | 9.63 ± 0.16   | 52.73 ± 3.69 | 57.25 ± 2.06 |
| Chromium picolinate-treated group |                   | 11.96 ± 1.43 | 6.83 ± 0.95     | 0.66 ± 0.38  | 2.26 ± 0.25 | 9.31 ± 0.92   | 50.50 ± 3.56 | 57.50 ± 1.90 |
| Chromium malate-treated group 1 |                   | 12.72 ± 1.87 | 5.84 ± 0.56     | 0.58 ± 0.18  | 2.20 ± 0.16 | 9.27 ± 0.16   | 52.58 ± 4.97 | 57.50 ± 1.73 |
| Chromium malate-treated group 2 |                   | 13.03 ± 1.07 | 6.20 ± 0.72     | 0.58 ± 0.11  | 2.31 ± 0.31 | 9.32 ± 0.18   | 51.87 ± 1.90 | 57.00 ± 3.00 |
| Chromium malate-treated group 3 |                   | 11.29 ± 4.54 | 6.84 ± 1.92     | 0.65 ± 0.23  | 1.87 ± 0.15 | 8.47 ± 0.39   | 49.35 ± 1.96 | 56.17 ± 1.47 |
| Chromium malate-treated group 4 |                   | 10.83 ± 2.30 | 6.72 ± 1.88     | 0.73 ± 0.11  | 1.92 ± 0.34 | 8.35 ± 0.45   | 49.58 ± 2.44 | 56.33 ± 1.97 |
| Chromium malate-treated group 5 |                   | 10.84 ± 2.22 | 6.33 ± 0.58     | 0.78 ± 0.23  | 1.89 ± 0.16 | 8.99 ± 0.02   | 49.70 ± 1.31 | 56.00 ± 2.65 |
| Chromium malate-treated group 6 |                   | 10.62 ± 1.64 | 7.00 ± 1.00     | 0.74 ± 0.22  | 1.89 ± 0.10 | 8.79 ± 0.23   | 49.97 ± 1.14 | 55.50 ± 1.52 |
| Chromium malate-treated group 7 |                   | 10.06 ± 1.69 | 7.95 ± 1.59     | 0.78 ± 0.44  | 1.76 ± 0.55 | 8.74 ± 0.09   | 49.58 ± 3.14 | 55.83 ± 1.72 |
| Chromium malate-treated group 8 |                   | 10.08 ± 1.71 | 7.68 ± 1.48     | 0.75 ± 0.16  | 1.61 ± 0.18 | 8.77 ± 0.65   | 49.78 ± 2.34 | 55.20 ± 1.84 |
| Chromium malate-treated group 9 |                   | 9.40 ± 1.59  | 7.47 ± 1.02     | 0.75 ± 0.12  | 1.59 ± 0.37 | 8.72 ± 0.26   | 47.70 ± 2.55 | 55.50 ± 2.74 |
| Chromium malate control group  |                   | 8.07 ± 1.65  | 9.61 ± 2.03     | 0.88 ± 0.26  | 1.19 ± 0.12 | 8.72 ± 0.23   | 49.98 ± 1.97 | 55.20 ± 1.84 |

Data is presented as mean ± standard deviation (n = 10). Chromium trichloride and chromium picolinate were used as positive controls. Hb, hemoglobin; HCT, hematocrit; LYMPH, lymphocyte count; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MnHbC, mean hemoglobin content; MNCC, mononuclear cell count; MPV, platelet mean volume; NCC, neutral cell count; PCT, platelet deposited; PDW, platelet distribution width; PLT, platelet count; RBC, red blood cell; RDW, red cell distribution width; WBC, white blood cell. †Significantly different from normal control group (P < 0.05).
**Table 5** | The changes of absolute and relative organ weights in normal rats and type 2 diabetic rats after administration chromium malate, chromium trichloride and chromium picolinate

| Absolute organ weight Group | Parameter | Heart | Liver | Spleen | Lung | Kidney | Brain |
|-----------------------------|-----------|-------|-------|--------|------|--------|-------|
| Normal control group        |           | 1.46 ± 0.19 | 15.07 ± 2.11 | 0.77 ± 0.14 | 1.94 ± 0.31 | 2.48 ± 0.41 | 1.59 ± 0.28 |
| Model group                 |           | 1.41 ± 0.21 | 16.38 ± 2.80 | 0.76 ± 0.25 | 2.03 ± 0.35 | 3.77 ± 0.32 | 1.74 ± 0.16 |
| Chromium trichloride-treated group | | 1.37 ± 0.12 | 14.43 ± 1.78 | 0.54 ± 0.11 | 1.98 ± 0.11 | 3.70 ± 0.36 | 1.82 ± 0.14 |
| Chromium picolinate-treated group | | 1.36 ± 0.15 | 16.31 ± 3.06 | 0.82 ± 0.25 | 1.91 ± 0.32 | 3.53 ± 0.36 | 1.76 ± 0.18 |
| Chromium malate-treated group 1 | | 1.37 ± 0.14 | 17.40 ± 2.42 | 0.90 ± 0.27 | 2.05 ± 0.17 | 3.58 ± 0.30 | 1.66 ± 0.16 |
| Chromium malate-treated group 2 | | 1.47 ± 0.19 | 16.36 ± 2.21 | 0.65 ± 0.11 | 2.19 ± 0.44 | 3.58 ± 0.43 | 1.82 ± 0.17 |
| Chromium malate-treated group 3 | | 1.33 ± 0.16 | 16.32 ± 0.79 | 0.83 ± 0.05 | 2.00 ± 0.36 | 3.51 ± 0.22 | 1.50 ± 0.15 |
| Chromium malate-treated group 4 | | 1.44 ± 0.14 | 17.98 ± 1.75 | 0.86 ± 0.13 | 2.03 ± 0.11 | 3.33 ± 0.66 | 1.84 ± 0.17 |
| Chromium malate-treated group 5 | | 1.44 ± 0.25 | 14.33 ± 1.14 | 0.57 ± 0.07 | 2.07 ± 0.28 | 3.50 ± 0.13 | 1.77 ± 0.21 |
| Chromium malate-treated group 6 | | 1.41 ± 0.23 | 15.68 ± 2.19 | 0.59 ± 0.14 | 2.01 ± 0.19 | 3.40 ± 0.08 | 1.82 ± 0.18 |
| Chromium malate-treated group 7 | | 1.35 ± 0.21 | 16.53 ± 2.48 | 0.77 ± 0.27 | 2.09 ± 0.39 | 3.25 ± 0.37 | 1.73 ± 0.19 |
| Chromium malate-treated group 8 | | 1.37 ± 0.10 | 15.21 ± 1.98 | 0.67 ± 0.24 | 2.01 ± 0.13 | 3.07 ± 0.76 | 1.79 ± 0.19 |
| Chromium malate-treated group 9 | | 1.27 ± 0.11 | 16.11 ± 2.87 | 0.87 ± 0.16 | 1.81 ± 0.28 | 3.02 ± 0.57 | 1.76 ± 0.15 |
| Chromium malate control group | | 1.54 ± 0.33 | 15.05 ± 1.52 | 0.88 ± 0.15 | 2.07 ± 0.26 | 2.41 ± 0.21 | 1.82 ± 0.28 |

| Relative organ weight Group | Parameter | Relative heart weight | Relative liver weight | Relative spleen weight | Relative lung weight | Relative kidney weight | Relative brain weight |
|-----------------------------|-----------|-----------------------|----------------------|-----------------------|----------------------|-----------------------|-----------------------|
| Normal control group        |           | 0.0028 ± 0.00039 | 0.029 ± 0.0043 | 0.015 ± 0.0029 | 0.0038 ± 0.00063 | 0.0048 ± 0.00084 | 0.0031 ± 0.00057 |
| Model group                 |           | 0.0034 ± 0.00025 | 0.039 ± 0.0053 | 0.018 ± 0.0030 | 0.0049 ± 0.00042 | 0.0090 ± 0.00038 | 0.0042 ± 0.00019 |
| Chromium trichloride-treated group | | 0.0034 ± 0.00024 | 0.036 ± 0.0035 | 0.013 ± 0.0022 | 0.0049 ± 0.00022 | 0.0092 ± 0.00071 | 0.0045 ± 0.00028 |
| Chromium picolinate-treated group | | 0.0031 ± 0.00026 | 0.037 ± 0.0053 | 0.019 ± 0.0043 | 0.0044 ± 0.00056 | 0.0081 ± 0.00063 | 0.0040 ± 0.00031 |
| Chromium malate-treated group 1 | | 0.0032 ± 0.00029 | 0.041 ± 0.0051 | 0.021 ± 0.0057 | 0.0048 ± 0.00036 | 0.0085 ± 0.00063 | 0.0039 ± 0.00034 |
| Chromium malate-treated group 2 | | 0.0034 ± 0.00041 | 0.038 ± 0.0034 | 0.015 ± 0.0017 | 0.0050 ± 0.00068 | 0.0082 ± 0.00066 | 0.0042 ± 0.00026 |
| Chromium malate-treated group 3 | | 0.0028 ± 0.00033 | 0.034 ± 0.0020 | 0.017 ± 0.0013 | 0.0042 ± 0.00092 | 0.0073 ± 0.00056 | 0.0031 ± 0.00038 |
| Chromium malate-treated group 4 | | 0.0031 ± 0.00032 | 0.038 ± 0.0041 | 0.018 ± 0.0030 | 0.0043 ± 0.00026 | 0.0071 ± 0.0015 | 0.0039 ± 0.00040 |
| Chromium malate-treated group 5 | | 0.0032 ± 0.00071 | 0.031 ± 0.0033 | 0.012 ± 0.0020 | 0.0045 ± 0.00080 | 0.0077 ± 0.00037 | 0.0039 ± 0.00060 |
| Chromium malate-treated group 6 | | 0.0028 ± 0.00053 | 0.032 ± 0.0051 | 0.012 ± 0.0032 | 0.0040 ± 0.00044 | 0.0069 ± 0.00019 | 0.0037 ± 0.00042 |
| Chromium malate-treated group 7 | | 0.0028 ± 0.00027 | 0.035 ± 0.0032 | 0.016 ± 0.0035 | 0.0044 ± 0.00050 | 0.0069 ± 0.00048 | 0.0037 ± 0.00024 |
| Chromium malate-treated group 8 | | 0.0029 ± 0.00017 | 0.032 ± 0.0035 | 0.014 ± 0.0042 | 0.0042 ± 0.00023 | 0.0064 ± 0.0013 | 0.0037 ± 0.00033 |
| Chromium malate-treated group 9 | | 0.0025 ± 0.00019 | 0.032 ± 0.0050 | 0.017 ± 0.0028 | 0.0036 ± 0.00049 | 0.0060 ± 0.00099 | 0.0035 ± 0.00026 |
| Chromium malate-control group | | 0.0032 ± 0.00012 | 0.031 ± 0.0053 | 0.018 ± 0.0052 | 0.0042 ± 0.00091 | 0.0049 ± 0.0073 | 0.0037 ± 0.00098 |

Data is presented as mean ± standard deviation (n = 10). Chromium trichloride and chromium picolinate was used as a positive control. †Significantly different from normal control group (P < 0.05). §Significantly different from model group (P < 0.05). ‡Significantly different from chromium trichloride-treated group (P < 0.05). ¶Significantly different from chromium picolinate-treated group (P < 0.05).
than that of normal rats. Insulin is a type of protein hormone and is secreted from pancreatic β-cells to control the blood glucose level\(^\text{33}\). It is a marker in the diagnosis and monitoring of type 2 diabetes, and is often used to control postprandial glucose levels in diabetics. Type 2 diabetes is also associated with insulin resistance and higher IR\(^\text{34}\). C-P is a small polypeptide produced and secreted from pancreatic β-cells during insulin synthesis. The concentration of C-P, which was secreted by β-cells, is equal to the insulin in the blood\(^\text{35}\). It is an important index for detection of insulin\(^\text{36}\). The results of the present study showed that the insulin, IR and C-P levels of type 2 diabetic rats were significantly higher than that of normal rats, and the results were similar to those in the literature. G6PD and GCK are key enzymes in glucose metabolism, and exist in the liver. The present results showed that the G6PD and GCK levels of type 2 diabetic rats were significantly lower than that of normal rats. Serum lipids, which include TC, LDL, HDL and TG, in type 2 diabetic rats changed significantly compared with the normal rats. Serum TC, LDL and TG levels in type 2 diabetic rats were significantly higher than that of normal rats. Serum HDL was significantly lower than that of normal rats. Król et al.\(^\text{38}\) found that chromium (III) propionate complex can significantly reduce serum TG, TC and LDL levels. Sharma et al.\(^\text{19}\) reported that chromium supplementation can significantly reduce TC, TG and LDL levels in type 2 diabetes. Sahin et al.\(^\text{27}\) reported that chromium picolinate (80 μg/kg bodyweight per day) can significantly reduce TC and TG when compared with type 2 diabetes mellitus. In conclusion, chromium malate shows beneficial effects against type 2 diabetes-induced glycometabolism, glycometabolism-related enzymes and lipid metabolism disorders. The antihyperglycemic activity of chromium malate is superior to chromium trichloride and chromium picolinate.

The loss of body mass often accompanies type 2 diabetes. Rodbard et al.\(^\text{38}\) reported that body mass control is a recommended treatment goal in type 2 diabetes patients: any weight gain of diabetes is associated with anti-diabetic therapy. Chromium malate can maintain the body mass of type 2 diabetic rats, whereas chromium trichloride and chromium picolinate cannot. Studies have shown that diabetes can cause biochemical and hematological changes\(^\text{39,40}\), and the results were similar to the present results. However, chromium malate has no significant effect on the biochemical and hematological index.

In conclusion, chromium malate shows greater benefits in treating type 2 diabetes, and can improve glycometabolism, glycometabolism-related enzymes and lipid metabolism in type 2 diabetic rats. The dose–response relationship of chromium malate showed that antihyperglycemic activity was increased with administration of chromium malate in a dose–dependent manner.

**ACKNOWLEDGMENTS**

This work was supported financially by the Specialized Research Fund for the Natural Science Foundation of China (31271850) and Graduate innovative projects in Jiangsu University (CXLX13_685). The authors declare no conflict of interest.

**REFERENCES**

1. Sudagani J, Hitman GA. Diabetes Mellitus: Etiology and Epidemiology. Encyclopedia of Human Nutrition, 3rd edn. Academic Press, New York, 2013.
2. Caballeró AE. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes. J Diabetes Complications 2009; 23: 143–152.
3. Cortez-Espinosa N, García-Hernández MH, Reynaga-Hernández E, et al. Abnormal expression and function of Dectin-1 receptor in type 2 diabetes mellitus patients with poor glycemic control (HbA1c>8%). Metabolism 2012; 61: 1538–1546.
4. Kelly PJ, Clarke PM, Hayes AJ, et al. Research: complications predicting mortality in people with Type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data. Diabet Med 2014; 18: 954–962.
5. Suge R, Shimazu T, Hasegawa H, et al. Cerebral antioxidant enzyme increase associated with learning deficit in type 2 diabetes rats. Brain Res 2012; 1481: 97–106.
6. Michelle CE, Monette MA, Anne B, et al. A meta-analysis of cognitive functioning in nondemented adults with Type 2 diabetes mellitus. Can J Diabetes 2014; 38: 401–408.
7. Halimi S. Do not forget that type 2 diabetes does not only expose to cardiovascular complications. Diabetes Metab 2014; 40: 167–168.
8. Ryan EA, Pick ME, Marceau C. Use of alternative medicines in diabetes mellitus. Diabet Med 2001; 18: 242–245.
9. Król E, Krejpcio Z. Chromium(III) propionate complex supplementation improves carbohydrate metabolism in insulin-resistance rat model. Food Chem Toxicol 2010; 48: 2791–2796.
10. Guerrero-Romero F, Tamez-Perez HE, González-González G, et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004; 30: 253–258.
11. Yu YM, Chang WC, Chang CT, et al. Effects of young barley leaf extract and antioxidative vitamins on LDL oxidation and free radical scavenging activities in type 2 diabetes. Diabetes Metab 2002; 28: 107–114.
12. Lin C, Chen PW, Chen WY, et al. Glucagon and insulin have opposite effects on tissue chromium distribution in an obese mouse model. J Diabetes Invest 2013; 6: 528–532.
13. Refaie FM, Esmat AY, Mohamed AF, et al. Effect of chromium supplementation on the diabetes induced-oxidative stress in liver and brain of adult rats. Biometals 2009; 22: 1075–1087.
14. Díaz-Medina EM, Martín-Herrera D, Rodríguez-Rodríguez EM, et al. Chromium(III) in cactus pad and its possible role in the antihyperglycemic activity. J Funct Foods 2012; 4: 311–314.
15. Ghosh D, Bhattacharya B, Mukherjee B, et al. Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 2002; 13: 690–697.

16. Chen PW, Lin C, Chen CD, et al. Chromium levels in insulin-sensitive tissues and the thigh bone are modulated by prednisolone and high-fat diets in mice. Biometals 2013; 26: 347–354.

17. Anderson RA. Chromium in the prevention and control of diabetes. Diabetes Metab 2000; 26: 22–27.

18. Król E, Krejpcio Z. Evaluation of anti-diabetic potential of chromium(III) propionate complex in high-fat diet fed and STZ injected rats. Food Chem Toxicol 2011; 49: 3217–3223.

19. Sharma S, Agrawal RP, Choudhary M, et al. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type 2 diabetes. J Trace Elem Med Biol 2011; 25: 149–153.

20. Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc 2004; 63: 41–47.

21. Gammelgaard B, Jensen K, Steffansen B. Role of chromium complexes in mice. Food Chem Toxicol 2005; 43: 1619–1625.

22. Whittaker P, San RHC, Clarke JJ, et al. Mutagenicity of chromium picolinate and its components in Salmonella typhimurium and LS178Y mouse lymphoma cells. Food Chem Toxicol 2005; 13: 690–1034.

23. Proctor DM, Suh M, Campleman SL, et al. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. Toxicology 2014; 325: 160–179.

24. Wu XY, Li F, Xu WD, et al. Anti-hyperglycemic activity of chromium(III) malate complex in alloxan-induced diabetic rats. Biol Trace Elem Res 2011; 143: 1031–1043.

25. Li F, Wu XY, Zou YM, et al. Comparing anti-hyperglycemic activity and acute oral toxicity of three different trivalent chromium complexes in mice. Food Chem Toxicol 2012; 50: 1623–1631.

26. Skovsø S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Invest 2014; 4: 349–358.

27. Yokokawa H, Kinoshita I, Hashiguchi T, et al. Enhanced exercise-induced muscle damage and muscle protein degradation in streptozotocin-induced type 2 diabetic rats. J Diabetes Invest 2011; 6: 423–428.

28. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci 2002; 103: 137–142.

29. Sereshti H, Khojeh V, Samadi S. Optimization of dispersive liquid–liquid microextraction coupled with inductively coupled plasma-optical emission spectrometry with the aid of experimental design for simultaneous determination of heavy metals in natural waters. Talanta 2011; 83: 885–890.

30. Meral I, Donmez N, Baydas B, et al. Effect of Nigella sativa L. on heart rate and some haematological values of alloxan-induced diabetic rabbits. Scand J Lab Anim Sci 2004; 1: 49–53.

31. Pattar GR, Tackett L, Liu P, et al. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 2006; 610: 93–100.

32. Tomihira M, Kawasaki E, Nakajima H, et al. Intermittent and recurrent hepatomegaly due to glycogen storage in a patient with type 1 diabetes: genetic analysis of the liver glycogen phosphorylase gene (PYGL). Diabetes Res Clin Pract 2004; 65: 175–182.

33. Pedersen MG, Cobelli C. Insulin Modelling. Modelling Methodology for Physiology and Medicine, 2nd edn. Academic Press, New York, 2014.

34. Ahna J, Lee H, Im SW, et al. Allyl isothiocyanate ameliorates insulin resistance through the regulation of mitochondrial function. J Nutr Biochem 2014; 25: 1026–1034.

35. Grueter CC, Deschner T, Behringer V, et al. Socioecological correlates of energy balance using urinary C-peptide measurements in wild female mountain gorillas. Physiol Behav 2014; 127: 13–19.

36. Liu TC, Chen MJ, Ren ZQ, et al. Development of an improved time-resolved fluorimunoassay for simultaneous quantification of C-peptide and insulin in human serum. Clin Biochem 2014; 47: 439–444.

37. Sahin K, Onderci M, Tuzcu M, et al. Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 2007; 56: 1233–1240.

38. Rodbard HW, Blonde L, Braithwaite SS, et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: 1–68.

39. Erukainure OL, Ebuehi OAT, Adeboyejo FO, et al. Hematological and biochemical changes in diabetic rats fed with fiber-enhanced cake. J Acute Med 2013; 3: 39–44.

40. Oyedemi SO, Adewusi EA, Ajegoro OA, et al. Antidiabetic and haematological effect of aqueous extract of stem bark of Afzelia africana (Smith) on streptozotocin-induced diabetic Wistar rats. Asian Pac J Trop Med 2011; 1: 353–358.